CARBONE MARCO

Role: 
Assistant Professor
Academic disciplines: 
GASTROENTEROLOGY (MED/12)

Biography

Dr Carbone is Senior Lecture at the University of Milano-Bicocca and Honorary Consultant Hepatologist at the European Reference Network-Liver Centre San Gerardo University Hospital, Monza where he is the clinical lead of the cholestatic liver disease programme.
He qualified in Medicine in Rome, Italy and trained in Hepatology in Birmingham and Cambridge, UK.
His research interest mainly relates to study disease mechanisms in cholestatic liver diseases. He runs a research programme in primary biliary cholangitis ad primary sclerosing cholangitis that encompasses joint modelling of molecular, biochemical and radiological data, and their conversion into meaningful outputs that can inform mechanistic understanding, health care decisions, and the design of innovative clinical trials. He is board member of the PBC Foundation and Council member of the Global Liver Institute. He is in the panel of the national guidelines for PBC and PSC and sit on the special interest group of the Italian Association of the Study of the Liver (AISF) for application of artificial intelligence in liver disease. In 2020 he received the “Young Investigator Lecture” award from the AISF and in 2021 he received “Rising Star” award from the United European Gastroenterology (UEG).

Publications

  • Carbone, M., Mells, G., Pells, G., Dawwas, M., Newton, J., Heneghan, M., et al. (2013). Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. GASTROENTEROLOGY, 144(3), 560-569. Detail
  • Carbone, M., Nardi, A., Flack, S., Carpino, G., Varvaropoulou, N., Gavrila, C., et al. (2018). Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. THE LANCET. GASTROENTEROLOGY & HEPATOLOGY, 3(9), 626-634. Detail
  • Carbone, M., Mells, G., Alexander, G., Westbrook, R., Heneghan, M., Sandford, R., et al. (2013). Calcineurin inhibitors and the IL12A locus influence risk of recurrent primary biliary cirrhosis after liver transplantation. AMERICAN JOURNAL OF TRANSPLANTATION, 13(4), 1110-1111. Detail
  • Carbone, M., & Neuberger, J. (2014). Autoimmune liver disease, autoimmunity and liver transplantation. JOURNAL OF HEPATOLOGY, 60(1), 210-223. Detail
  • Carbone, M., Sharp, S., Flack, S., Paximadas, D., Spiess, K., Adgey, C., et al. (2016). The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. HEPATOLOGY, 63(3), 930-950. Detail